6-amino-5-benzylamino-1(p-methoxybenzyl)-uracil | 158893-88-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 6-amino-5-benzylamino-1(p-methoxybenzyl)-uracil
• 英文别名: 6-Amino-5-benzylamino-1-(4-methoxybenzyl)uracil；6-amino-5-(benzylamino)-1-[(4-methoxyphenyl)methyl]pyrimidine-2,4-dione
• CAS: 158893-88-0
• 化学式: C₁₉H₂₀N₄O₃
• 分子量: 352.393
• InChiKey: AMNKYMYKGZECBX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.16
• 拓扑面积：
  96.7
• 氢给体数：
  3
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  6-amino-5-benzylamino-1(p-methoxybenzyl)-uracil 、 1-adamantanecarbonyl chloride 在 盐酸 、 2-二甲氨基吡啶 作用下， 以 N-甲基乙酰胺 为溶剂， 以20.35 g (85%)的产率得到6-Amino-5-(N-benzyl-N-(noradamantylcarbonyl))amino-1(p-methoxybenzyl)-uracil
  参考文献：
  名称：

  Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity

  摘要：

  具有腺苷A1受体拮抗活性的非对称取代黄嘌呤衍生物，可用作药物。例如：(a)3-(2-(2-乙酰氧乙基)磺酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤；(b)3-(2-(羟乙基)磺酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤；(c)3-(2-(氨基甲酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤。

  公开号：

  US06187780B1

文献信息

• Fused purine derivatives
  申请人：——

  公开号：US20030176698A1

  公开（公告）日：2003-09-18

  A condensed purine derivative represented by Formula (I): 1 wherein X—Y—Z represents R 1 N—C═O or N═C—W, R 2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V 1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V 2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V 1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X—Y—Z represents R 1a N—C═O and R 2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, —NR 7 R 8 , —CO 2 H, a lower alkoxycarbonyl group, —COHal, —CONR 9 R 10 or —CHO, V 2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  一个由公式(I)表示的浓缩嘌呤衍生物：1 其中，X—Y—Z代表R1N—C═O或N═C—W，R2代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团、取代或未取代的芳香杂环团、取代或未取代的脂肪杂环团等，n代表从0到3的整数，V1代表氢原子、取代或未取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的芳基团或取代或未取代的芳香杂环团，V2代表取代的低级烷基团或取代或未取代的芳香杂环团，并且当V1代表氢原子、低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团时，例如，X—Y—Z代表R1aN—C═O并且R2代表取代的低级烷基团、取代或未取代的芳烷基团、取代或未取代的脂肪杂环团、卤素原子、低级烷基亚硫酰基团、—NR7R8、—CO2H、低级烷氧羰基团、—COHal、—CONR9R10或—CHO，V2可以代表低级烷基团、取代或未取代的芳烷基团或取代或未取代的芳基团；或其药理可接受的盐。
• FUSED PURINE DERIVATIVES
  申请人：KYOWA HAKKO KOGYO CO., LTD.

  公开号：EP1251130A1

  公开（公告）日：2002-10-23

  A condensed purine derivative represented by Formula (I): wherein X--Y--Z represents R1N-C=O or N=C-W, R2 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, a substituted or unsubstituted aromatic heterocyclic group, a substituted or unsubstituted alicyclic heterocyclic group or the like, n represents an integer of from 0 to 3, V1 represents a hydrogen atom, a substituted or unsubstituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted aryl group, or a substituted or unsubstituted aromatic heterocyclic group, V2 represents a substituted lower alkyl group or a substituted or unsubstituted aromatic heterocyclic group, and when V1 represents a hydrogen atom, a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group, and for example, X--Y--Z represents R1aN-C=O and R2 represents a substituted lower alkyl group, a substituted or unsubstituted aralkyl group, a substituted or unsubstituted alicyclic heterocyclic group, a halogen atom, a lower alkylthio group, -NR7R8, -CO2H, a lower alkoxycarbonyl group, -COHal, -CONR9R10 or -CHO, V2 may represent a lower alkyl group, a substituted or unsubstituted aralkyl group, or a substituted or unsubstituted aryl group; or a pharmacologically acceptable salt thereof.

  由式(I)代表的缩合嘌呤衍生物： 其中 X--Y--Z代表 R1N-C=O或N=C-W，R2代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基、取代或未取代的芳香杂环基团、取代或未取代的脂环杂环基团或类似基团，n代表0至3的整数，V1代表氢原子、V1 代表氢原子、取代或未取代的低级烷基、取代或未取代的芳烷基、取代或未取代的芳基或取代或未取代的芳杂环基团、V2 代表取代的低级烷基或取代的或未取代的芳杂环基团，当 V1 代表氢原子、低级烷基、取代的或未取代的芳烷基或取代的或未取代的芳基时，例如，X--Y--Z 代表 R1aN-C=O，R2 代表取代的低级烷基、取代或未取代的芳烷基、取代或未取代的脂环杂环基、卤素原子、低级烷硫基、-NR7R8、-CO2H、低级烷氧基羰基、-COHal、-CONR9R10 或 -CHO，V2 可代表低级烷基、取代或未取代的芳烷基或取代或未取代的芳基；或其药理学上可接受的盐。
• US6187780B1
  申请人：——

  公开号：US6187780B1

  公开（公告）日：2001-02-13
• US7005430B2
  申请人：——

  公开号：US7005430B2

  公开（公告）日：2006-02-28
• Assymetrically substituted xanthine derivatives having adenosine A1 antagonistic activity
  申请人：Boehringer Ingelheim Pharma KG

  公开号：US06187780B1

  公开（公告）日：2001-02-13

  Asymmetrically substituted xanthine derivatives having adenosine A1 antagonistic activity. These are useful as pharmaceuticals. Exemplary are: (a) 3-(2-(2-acetyloxyethyl)sulphonylethyl)-8-(1-noradamantyl)-1-n-propyl-xanthine; (b) 3-(2-(hydroxyethyl)sulphonylethyl)-8-(1-noradamantyl)-1-n-propyl-xanthine; and, (c) 3-(2-(carbamoylethyl)-8-(1-noradanantyl)-1-n-propyl-xanthine.

  具有腺苷A1受体拮抗活性的非对称取代黄嘌呤衍生物，可用作药物。例如：(a)3-(2-(2-乙酰氧乙基)磺酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤；(b)3-(2-(羟乙基)磺酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤；(c)3-(2-(氨基甲酰乙基)-8-(1-去甲密环烷基)-1-正丙基黄嘌呤。